Adaptive Biotechnologies (ADPT) CPO sells 39,741 shares after option exercises
Rhea-AI Filing Summary
Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported a series of stock option exercises and a same-day share sale in Common Stock. On June 4, 2026, Lo exercised options covering 19,521 shares at strike prices ranging from $3.99 to $12.14 per share, receiving an equivalent number of common shares.
On the same date, Lo completed an open-market sale of 39,741 Common Stock shares at an average price of $17.49 per share. Following these transactions, Lo holds 250,934 Common Stock shares directly and 2,500 shares indirectly through a spouse. The filing notes that these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
10 txns
Insider
LO FRANCIS
Role
Chief People Officer
Sold
39,741 shs ($695K)
Approx. gross sale proceeds
$695K
Approx. exercise cost
$173K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 5,792 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 2,009 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 2,344 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 9,376 | $0.00 | $0.00 |
| Exercise | Common Stock | 5,792 | $12.14 | $70K |
| Exercise | Common Stock | 2,009 | $8.46 | $17K |
| Exercise | Common Stock | 2,344 | $3.99 | $9K |
| Exercise | Common Stock | 9,376 | $8.12 | $76K |
| Sale | Common Stock | 39,741 | $17.49 | $695K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 483,489 shares (Direct);
Common Stock — 250,934 shares (Direct);
Common Stock — 2,500 shares (Indirect, By You Jin Lee (spouse))
Footnotes (5)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
- F2. The option is fully vested and exercisable.
- F3. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
- F4. The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
- F5. The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Key Figures
Shares sold: 39,741 shares
Sale price: $17.49 per share
Options exercised: 19,521 shares
+4 more
7 metrics
Shares sold
39,741 shares
Common Stock open-market sale on June 4, 2026 at $17.49
Sale price
$17.49 per share
Average price for 39,741 Common Stock shares sold
Options exercised
19,521 shares
Total Common Stock from option exercises on June 4, 2026
Post-transaction direct holdings
250,934 shares
Common Stock directly held by Francis Lo after transactions
Indirect holdings via spouse
2,500 shares
Common Stock held by spouse, reported as indirect ownership
Lowest option strike
$3.99 per share
One of the stock option exercise prices
Highest option strike
$12.14 per share
One of the stock option exercise prices
Key Terms
Rule 10b5-1 trading plan, open-market sale, Stock Option (right to buy), Chief People Officer
4 terms
Rule 10b5-1 trading plan regulatory
"transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Stock Option (right to buy) financial
"security_title": "Stock Option (right to buy)""
Chief People Officer financial
"officer_title": "Chief People Officer""
A chief people officer is a senior executive responsible for overseeing a company's workforce and human resources strategies. They focus on attracting, developing, and retaining employees, ensuring a positive workplace culture, and aligning staff efforts with the company's goals. For investors, this role matters because strong leadership in managing people can drive productivity, innovation, and overall company performance.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did ADPT Chief People Officer Francis Lo report?
Francis Lo reported option exercises and an open-market sale of Adaptive Biotechnologies Corp Common Stock. He exercised options for 19,521 shares, then sold 39,741 shares at $17.49 per share, with all activity occurring on June 4, 2026 under a trading plan.
Were Francis Lo’s Adaptive Biotechnologies trades under a Rule 10b5-1 plan?
Yes. The Form 4 states that the transactions were effected under a Rule 10b5-1 trading plan adopted on September 15, 2025. Such plans pre-schedule trades, indicating the timing of these June 2026 transactions was established in advance rather than decided opportunistically.
What stock options did Francis Lo exercise in this ADPT Form 4?
Francis Lo exercised options covering 19,521 shares of Adaptive Biotechnologies Corp Common Stock. The exercised options had strike prices including $3.99, $8.12, $8.46, and $12.14 per share, converting these derivative positions into common shares on June 4, 2026.